OR WAIT null SECS
June 18, 2025
Article
Findings highlight an increased risk of MASLD, heart failure, type 2 diabetes, and other cardiometabolic diseases following cycles of weight loss and regain.
June 14, 2025
An audio recap of the top 5 stories in healthcare news from the week of 06/02-06/08.
Stay updated with the latest healthcare breakthroughs, including FDA approvals and new phase 3 clinical trial data, in this week's essential news roundup.
June 13, 2025
Successful HCV treatment with DAAs was associated with reduced risks of CKD, stroke, major adverse cardiac events, and neurocognitive disorders.
June 12, 2025
The label expansion makes glecaprevir/pibrentasvir the first and only oral 8-week pangenotypic treatment option approved for people with acute or chronic HCV.
June 11, 2025
Mortality from ALD rose significantly across most demographic groups in the US from 1999 to 2022, especially during and following the COVID-19 pandemic onset.
Podcast
In the second part of a 2-part episode, hosts Kimberly Brown and Nancy Reau break down 3 more notable abstracts from the 2025 EASL Congress.
June 05, 2025
The month in review spotlights hepatic podcast episodes from HCPLive, new clinical trial data, and coverage from DDW.
June 04, 2025
Video
Alkhouri reviews data from the trial’s open-label compensated MASH cirrhosis arm demonstrating resmetirom’s impact on liver stiffness and CSPH.
Hosts discuss a consensus repot from the ADA focused on screening and early interview of MASLD in people with diabetes.
